Sutro Biopharma Dividend
Dividend criteria checks 0/6
Sutro Biopharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$1.39 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07Sutro: Leading Cell Free Protein Synthesis Company With Promising Early Data
Jan 06Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Jan 06
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if STRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STRO's dividend payments have been increasing.
Dividend Yield vs Market
| Sutro Biopharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (STRO) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.9% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (STRO) | 0% |
Notable Dividend: Unable to evaluate STRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate STRO's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as STRO has not reported any payouts.